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Abstract (271 words) 
 
Background  
Image guided radiotherapy (IGRT) improves treatment set-up accuracy and provides the 
opportunity to reduce target volume margins. We introduced IGRT methods using standard 
(IGRT-S) or reduced (IGRT-R) margins in a randomised phase 2 substudy within the CHHiP 
trial. We present a pre-planned analysis of the impact of IGRT on dosimetry and acute/late 
pelvic side effects using gastrointestinal and genitourinary clinician and patient-reported 
outcomes (PRO) and evaluate efficacy. 
 
Methods 
CHHiP is a randomised phase 3, non-inferiority trial for men with localised prostate cancer. 
3216 patients were randomly assigned to conventional (74 Gray (Gy) in 2Gy/fraction (f) 
daily) or moderate hypofractionation (60 or 57Gy in 3Gy/f daily) between October 2002 and 
June 2011.  The IGRT substudy included a second randomisation assigning to no-IGRT, IGRT-
S (standard CTV-PTV margins), or IGRT-R (reduced CTV-PTV margins). The primary substudy 
endpoint was late RTOG bowel and urinary toxicity at 2 years post-radiotherapy.  
 
Findings 
Between June 2010 to July 2011, 293 men were recruited from 16 centres (48 no-IGRT, 137 
IGRT-S and 108 IGRT-R). Median follow-up is 56.9 months (IQR 54.3-60.9). Rectal and 
bladder dose-volume and surface percentages were significantly lower in IGRT-R compared 
to IGRT-S group (p<0.0001). The cumulative proportion with RTOG grade>2 toxicity reported 
to 2 years for bowel was 8.3(95% CI 3.2-20.7)%, 8.3(4.7-14.6)% and 5.8(2.6-12.4)% and for 
urinary 8.4(3.2-20.8)%, 4.6(2.1-9.9)% and 3.9(1.5-9.9)% in the no IGRT, IGRT-S and IGRT-R 
groups respectively. In an exploratory analysis, treatment efficacy appeared similar in all 
three groups.  
 
Interpretation 
Introduction of IGRT was feasible in a national randomised trial and IGRT-R produced 
dosimetric benefits. Overall side effect profiles were acceptable in all groups but lowest 
with IGRT and reduced margins. 
Funding 
Cancer Research UK, Department of Health, and the National Institute of Health Research 
Cancer Research Network 
 
 
Introduction  
 
Intensity-modulated radiotherapy (IMRT) enables dose escalation to the prostate target 
volume, with low gastrointestinal or genitourinary toxicity.1–4 The success of radical prostate 
radiotherapy depends on accurate delivery of high dose conformal radiotherapy to a 
defined target volume. Image guided radiotherapy (IGRT) with daily online imaging has the 
potential to improve prostate localisation, consequently improving treatment accuracy and 
reducing the required clinical to planning target volume margin.5 This may result in less 
normal tissue receiving target doses, and consequently less toxicity.6  
 
However, to enable online daily IGRT, either an additional invasive procedure for insertion 
of fiducial markers into the prostate is required or availability of treatment equipment 
enabling soft tissue matching is needed. Intrafraction motion and outlining uncertainties 
necessitate a small margin around the target volume.5  
 
In addition to optimising prostate radiotherapy techniques, there has been interest in the 
exploitation of fraction sensitivity of prostate cancer through hypofractionation.7–9 This has 
been successfully examined within the UK multicentre randomised controlled trial 
(Conventional or Hypofractionated High-dose Intensity Modulated Radiotherapy in Prostate 
Cancer; CHHiP) which aimed to compare the efficacy and toxicity of conventional and 
hypofractionated radiotherapy using high-quality radiation techniques. Within the trial, 
3216 patients were enrolled from 71 centres within the UK between October 2002 and June 
2011.10  
 
During the latter stages of the CHHiP trial, IGRT became available in participating treatment 
centres. Rather than this technology being introduced into the CHHiP trial in a piecemeal 
fashion, the CHHiP IGRT phase 2 substudy was developed. We aimed to determine the 
feasibility and generalisability of IGRT in the context of a multicentre trial and assess acute 
and late toxicity. A patient reported outcome (PRO) protocol was subsequently integrated 
into the substudy. To our knowledge, this is the only randomised study of prostate IGRT 
undertaken worldwide.  
 
 
Methods  
 
Study design and participants 
CHHiP is a randomised phase 3, non-inferiority trial which recruited men with localised 
prostate cancer (pT1b-T3aN0M0).10 Patients were randomly assigned (1:1:1) to 
conventional 74 Gray (Gy) in 2Gy/fraction (f) daily or one of two hypofractionated schedules 
giving 60Gy or 57Gy in 3Gy/f daily. Patients were all treated with intensity modulated 
radiotherapy.11  
 
The IGRT substudy was implemented following a separate ethics application in June 2010 
and approved by Central London REC1 Research Ethics Committee (10/H0718/31). Men who 
had entered the CHHiP trial were eligible for the IGRT substudy provided they had no 
contraindication to implanted fiducial markers or a hip prosthesis or fixation which would 
interfere with positional imaging. A separate consent was required for the IGRT substudy in 
addition to the main trial entry. Treatment allocation to the IGRT substudy occurred 
immediately following randomisation to the CHHiP trial. Minimisation was used to assign 
patients in a 1:1:1 ratio to either no-IGRT – using standard CHHiP planning margins, IGRT 
using standard CHHiP planning margins (IGRT-S), or IGRT with reduced planning margins 
(IGRT-R), with radiotherapy centre and dose/fractionation schedule as balancing factors. 
Neither patients nor clinicians were blinded to treatment allocation. Sixteen UK 
radiotherapy centres took part in this substudy. Centres could choose depending on 
previous IGRT experience to randomise among all three options or no IGRT versus IGRT-S or 
IGRT-S versus IGRT-R. In 2014, a patient reported outcomes (PRO) assessment was 
introduced to collect data at a single time point at least 3 years post randomisation. This 
separate protocol received ethical approval from the NRES Committee South West – Central 
Bristol (14/SW/1071).  
 
Treatment 
Patients randomised to treatment with IGRT, either had fiducial markers inserted into the 
prostate using trans-rectal ultrasound guidance or soft tissue matching if using the 
TomoTherapy® system. Fiducial markers were implanted with antibiotic cover 
approximately 2 weeks prior to the radiotherapy planning scan. Patient positioning was 
supine and target and treatment planning volumes have been previously described.11 
Treatment was planned and delivered using an integrated simultaneous boost technique 
(SIB) with three different target volumes and dose levels as previously detailed12 and 
illustrated in Table S1. Mandatory dose constraints were defined for both target coverage 
and avoidance of normal tissues including rectum, bowel, bladder and femoral heads (Table 
S2). Treatment was delivered with 6-15 MV photons with multileaf collimators to shape 
beams. 
Patients randomised to no-IGRT, had offline portal imaging to verify treatment accuracy, 
which was to be within 3mm.  Patients receiving IGRT had daily pre-treatment imaging and 
any observed set-up error >2mm was corrected prior to treatment. No post-correction 
imaging was required. A quality-assurance programme previously detailed was designed as 
an integral part of the study.12  
 
Trial assessments 
Pre-trial staging investigations included PSA, lymph node assessment by MRI or CT, and 
bone scan. Histology was assessed from diagnostic TRUS guided biopsies (or TURP 
specimens) and reported using the Gleason system.  
Toxicity experienced from fiducial marker insertion was recorded using CTCAE grading.13 
Pre-hormone and pre-radiotherapy clinical assessments used Late Effects of Normal Tissues 
Subjective-Objective Management (LENT-SOM)14 and the Royal Marsden Hospital (RMH) 
grading.15 Clinical assessment of acute toxicity was made weekly during radiotherapy and at 
weeks 10, 12 and 18 from the start of radiotherapy using the Radiation Therapy Oncology 
(RTOG) scoring system.16 Late toxicity was assessed at 6, 12, 18 and 24 months then 
annually to 5 years using RTOG, LENTSOM and RMH scoring systems.  
In the PRO substudy, data was collected at a single time point using the Expanded Prostate 
Cancer Index Composite (EPIC) questionnaire, (EPIC-50 used for bowel and urinary domains 
and EPIC-26 for sexual and hormonal domains) 17, the Vaizey Incontinence18, Short Form 12 
(SF-12)19 and International Index of Erectile Function (IIEF-5)20 questionnaires. 
Questionnaires were sent directly from participating centres to patients (following 
confirmation of health status) who were ≥3 years from completing treatment. A single 
reminder letter was sent.  
 
For each patient, the treatment planning data (planning CT, dose distribution and organ 
contours) were uploaded using dedicated analysis software (VODCA, MSS Medical Software 
Solutions, Hagendorn, Switzerland). Using in-house code, all radiotherapy plans were 
converted into equivalent dose in 2Gy per fraction, using Withers formula21 with an α/β 
ratio of 3Gy for rectum and 5Gy for bladder.  Dose volume (DVH) and dose-surface (DSH) 
histograms were generated for the rectum and bladder.  
 
Statistical considerations 
The IGRT substudy was non-comparative and powered to assess toxicity independently 
within each treatment group using a Simon single stage design with exact p-values. The 
primary endpoint was the proportion of patients with RTOG bladder or bowel toxicity of 
grade≥2 at two years from starting radiotherapy. Secondary endpoints included acute 
toxicity, the prevalence of late radiation induced toxicity, time to late radiation induced 
toxicity, toxicity associated with fiducials and feasibility of delivery of IGRT in a multi-centre 
setting. Efficacy has been included as exploratory analyses. Ninety-one patients were 
required (with 79 or more remaining toxicity-free) in each group to give 80% power to 
detect a 10% RTOG bladder/bowel grade≥2 toxicity rate at 2 years with IGRT assuming a 
20% toxicity rate with no IGRT (alpha 3.4%). A sample size was not calculated for the PRO 
substudy, all eligible IGRT substudy patients were invited to participate. 
 
Analysis methods 
All analyses have been presented according to randomly allocated IGRT group. Descriptive 
statistics and boxplots have been used to present treatment planning data. Analyses of side 
effects included all data available at each time point for patients who received at least one 
fraction of radiotherapy (unless otherwise stated).  Acute and late toxicity have been 
presented as stacked bar charts and the prevalence of grade≥1, grade≥2 and grade≥3 at 
each time point. Worst acute bladder and bowel toxicity was calculated using the worst 
grade reported during the first 18 weeks from the start of radiotherapy. For the primary 
endpoint, only patients with a 2 year RTOG toxicity assessment were included in the 
denominator, although a sensitivity analysis was conducted using all randomised patients. 
The proportion of patients with RTOG bladder or bowel toxicity of grade≥2 at 2 years were 
presented together with exact binomial 95% confidence intervals. Time to first occurrence 
of late radiation induced side effects of grade≥1 and grade≥2 were analysed using the 
Kaplan Meier method to calculate the cumulative proportion with events reported on the 2 
year assessment form for each scoring system. Time was measured from the start of 
radiotherapy. Patients not experiencing an event were censored at date of last toxicity 
assessment or at date of death for deceased patients. The log-rank test was used to 
compare no IGRT versus IGRT-S and IGRT-S versus IGRT-R with a significance level of 1%, to 
account for multiple comparisons. Biochemical/clinical failure was defined as time to first 
PSA failure (PSA value greater than nadir +2ng/ml with a consecutive confirmatory PSA 
value) or prostate cancer recurrence (local, lymph node, pelvic or distant). Patients event 
free at the time of analysis were censored at their last know PSA assessment. 
 
Statistical analyses were based on a data snapshot taken on 18th May 2016 (except for 
efficacy analyses which were based on a snapshot taken on 3rd April 2018 to maximise data 
maturity). All analyses were performed using STATA Version 13.1. Patient reported 
outcomes were scored in accordance with the recommended scoring manuals22,23 and 
presented as descriptive statistics by treatment group.  The Vaizey questionnaire is scored 
on a continuous scale, with minimum score, 0 representing perfect continence and a 
maximum score, 24 representing total incontinence.18 Patients were divided into 3 
categories for Vaizey total score according to tertiles and dose data presented. In health 
related quality of life, the clinically meaningful change is defined as a mean change score 
exceeding half the standard deviation of the baseline value.24 As there was no baseline data 
available for this patient group, the mean and standard deviation values from the main 
CHHiP trial QoL substudy25 (Table S3) were used to define a threshold score for a meaningful 
change for the EPIC bowel and urinary domain scores. 
 
Results  
Two-hundred and ninety-three patients (48 no-IGRT, 137 IGRT-S and 108 IGRT-R) were 
randomised from 16 radiotherapy centres across the UK between July 2010 and June 2011. 
Baseline characteristics were balanced between treatment groups (Table 1) with a median 
age of 71 (IQR 66-74), median pre-hormone PSA of 9.5ng/ml (IQR 6.8-12.40) and 12%, 77% 
and 11% low, intermediate and high risk respectively. At the time of the data snapshot for 
toxicity median follow-up was 56.9 months (IQR 54.3-60.9) and for efficacy 73.3 (IQR 64.9-
74.6) months.  
 
Radiotherapy 
Three patients received no radiotherapy (one withdrew consent, one died and one 
biochemically progressed prior to radiotherapy). Adherence to randomly allocated 
treatment was high (Figure 1): 3 no-IGRT patients received IGRT, 8 IGRT-S patients did not 
receive standard CHHiP planning margins and 4 IGRT-R patients did not have reduced 
margins.  
Median (IQR) rectum volumes were 65 (59-77), 68 (56-86) and 67 (58-85) cm3 for the no-
IGRT, IGRT-S and IGRT-R groups respectively. Corresponding figures for bladder volumes 
were 277 (200-379), 249 (167-375) and 281 (180-386) cm3 (Table S4). A summary of DVH 
and DSH for rectum and bladder by treatment group are shown in Figure 2. Both rectal and 
bladder dose volume and surface percentages were consistently statistically lower in the 
IGRT-R compared to IGRT-S group (Table S5). 
 
Acute toxicity 
Toxicity associated with fiducial marker insertion was minimal with 19/190 (10%) reporting 
grade 1 and one patient reporting grade 2 haemorrhage. Six (3%) patients had an infection, 
three grade 1, two grade 2 and one grade 3. Worst RTOG bowel toxicity reported during 18 
weeks from starting radiotherapy was grade≥2 in 13/48 (27%), 38/135 (28%) and 26/107 
(24%) of no-IGRT, IGRT-S and IGRT-R patients respectively. Corresponding figures for RTOG 
bladder grade≥2 were 21/48 (44%), 71/135 (53%) and 48/107 (45%). By week 18, the 
majority of toxicity had resolved with grade≥2 bowel toxicity reported in 0% no-IGRT, 5% 
IGRT-S and 2% IGRT-R patients and RTOG bladder grade≥2 reported in 3% no-IGRT, 8% IGRT-
S and 4% IGRT-R patients (Figure 3). 
 
Late toxicity 
At two years, RTOG bowel and bladder toxicity was low across all groups (Table S6) with 13 
out of 274 (4.7%) patients assessed reporting any RTOG grade≥2 toxicity, which was the 
primary endpoint of the substudy. The upper limits of 95% confidence intervals ruled out 
greater than 20% toxicity within each treatment group. Moderate to severe RTOG bowel 
toxicity was similar across treatment groups, with 1/46 (2%), 3/125 (2%) and 2/103 (2%) no-
IGRT, IGRT-S and IGRT-R patients reporting grade≥2 at 2 years. The cumulative proportion 
with grade≥2 RTOG bowel toxicity reported to 2 years was 8.3% (95%CI 3.2-20.7), 8.3% (4.7-
14.6%) and 5.8% (2.6-12.4%) for no-IGRT, IGRT-S and IGRT-R groups respectively (Figure 4A 
and Table S6).  RMH and LENTSOM scales showed similar low levels of moderate to severe 
bowel/rectum toxicity. RMH bowel grade≥2 showed reduced toxicity in the IGRT-R group 
compared to IGRT-S with borderline statistical significance (HR=0.39, 95%CI 0.18-0.83, 
p=0.012).  
 
Moderate to severe RTOG bladder toxicity was similar across treatment groups, with 1/46 
(2%), 4/125 (3%) and 2/103 (2%) no-IGRT, IGRT-S and IGRT-R patients reporting grade≥2 at 2 
years. The cumulative proportion of RTOG bladder grade≥2 toxicity by 2 years was low for 
all groups with the least toxicity reported in the IGRT-R group: 8.4 (3.2-20.8)%, 4.6 (2.1-
9.9)% and 3.9 (1.5-9.9)% for no-IGRT, IGRT-S and IGRT-R groups respectively (Figure 4B and 
Table S7). The RMH and LENTSOM scales reported higher incidences of bladder toxicity 
compared to RTOG but with a similar trend across groups. There was no evidence of 
significant differences between treatment groups. 
 
Patient reported outcomes 
A total of 193/265 (72.8%) PRO booklets were completed at a median of 50.3 months (IQR 
47.8-52.0) from randomisation. Baseline characteristics were balanced between treatment 
groups and there were no significant differences between patients who did and did not 
complete the PRO booklet (Table S8). There was no evidence of any differences between 
treatment groups for EPIC or Vaizey summary scores (Table 2). There was no suggestion of a 
worsening of Vaizey score with increased dose volume or dose surface at any dose level 
(Table S9). The median DVH and DSH values were calculated for patients whose EPIC bowel 
and urinary scores were below and above the threshold level previously defined. There was 
a trend that patients whose score were below the cut-point had higher dose volume or 
surface levels (Figure S1).  
 
Efficacy 
Thirty-three patients had biochemical/clinical failure reported (4, 20 and 9 in the no IGRT, 
IGRT-S and IGRT-R groups respectively) (Table S10 and Figure S2). Five-year 
biochemical/clinical failure free survival was 91.1 (95% CI 77.9-96.6), 85.2 (95%CI 77.7-90.3) 
and 93.1 (95%CI 86.1-96.7) for no IGRT, IGRT-S and IGRT-R groups respectively. Fourteen 
patients had recommenced androgen deprivation therapy, nine had local recurrence, seven 
had lymph node/pelvic recurrence and seven had distant recurrence. Twenty-seven patients 
had died, three from prostate cancer, twenty-three from other reasons and one unknown.  
 
 
Discussion  
We have demonstrated that implementation of IGRT was feasible in a multi-centre trial in 
the UK. Recruitment of patients was swift, and completed within one year. Accrual peaked 
at 45 patient/month, with 16 radiotherapy centres participating. Subsequently IGRT has 
become part of the national guidelines recommended treatment pathway emphasising the 
potential of a clinical trial as a vehicle to introduce advanced radiotherapy technology. 
Limitations of this substudy include it’s relatively small size, uneven randomisation between 
groups and PRO assessment at a single time point. Yet, to our knowledge, this is the only 
randomised prospective study evaluating no-IGRT, IGRT and treatment margins using the 
same planning techniques. 
We found minimal toxicity associated with insertion of fiducial markers. Dosimetric 
assessments showed that reduced margins in the IGRT-R group resulted in rectal and 
bladder volumes receiving 5-65Gy being significantly lower (<0.0001) than using standard 
margins, this was also seen for surface dose. The mean dose to the rectal surface in the 
IGRT-S group was  33.9(±5.1) Gy and similar to that previously reported of 34.4(±7.2)Gy 
using IG-IMRT26 despite differences in dose prescription and margining techniques. As 
expected, the mean dose to the rectum in the IGRT-R group was significantly lower at 
28.9(±4.2)Gy. Similarly, the mean dose to bladder surface was 26.6(±9.2)Gy / 20.5(±6.6)Gy 
for IGRT-S / IGRT-R groups respectively, both lower than previously reported (33.1 ± 10.9Gy) 
(26). Late GI toxicity was consistently reported less often using the three clinician based 
scores in the IGRT-R group. However, the improved rectal dosimetry did not translate into a 
statistically significant benefit in acute or late GI toxicity, with the possible exception of 
grade≥2 RMH GI side-effects. This perhaps unexpected result may relate to the low level of 
side-effects seen in all randomised groups in the main CHHiP trial which used strict normal 
tissue dose constraints and a SIB technique limiting dose to the seminal vesicles.10 The lack 
of improvement in acute and late GU side effects may relate to similar doses to the urethra 
in all treatment groups. It maybe the combination of dose/volume/fractionation employed 
in the trial has reached a plateau for radiotherapy side effects and other patient27, 
radiogenomic28 or microbiota29 related factors become more important in determining 
residual symptoms. We believe it imprudent to extrapolate to treatments using higher 
doses, treating larger target volumes or using more extreme forms of hypofractionation 
where the clinical benefits of IGRT-R might be more apparent. Previous studies comparing 
patient cohorts treated with IG-IMRT and 3D-CFRT26,27 have suggested improvements in 
grade≥2 GU or GI side-effects using IGRT but are compromised by differences in planning 
and delivery techniques as well as differing dose constraints. It has also been suggested that 
high-dose IGRT improves disease control.9 IGRT may increase accuracy and reduce the 
chance of underdosage in the target volume, alternatively however it is possible that the 
reduced margins might lower inadvertent dose outside the prostate which has been 
suggested as a cause of treatment failure.30 However, we found no evidence to suggest that 
IGRT was associated with a reduction in disease control.  
The IGRT experience gained within this study has facilitated development of a new national 
trial PIVOTALboost (CRUK/16/018) in which all patients receive IG-IMRT and are randomised 
to receive pelvic lymph node IMRT or MR-directed dominant lesion boosts using 
hypofractionated schedules as in the CHHiP study. 
 
We have shown it is feasible to introduce prostate IGRT in a national randomised trial and 
that reduced margins translate into dosimetric benefits. Overall side effect profiles were low 
with/without IGRT in the CHHiP trial and this substudy.  
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